Goldman Sachs Group Inc Spruce Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$1.15 - $3.17 $187,568 - $517,036	163,103 Added 834.16%	182,656 $403,000
Q1 2023 May 11, 2023	BUY	$1.15 - $3.17 $210,054 - $579,019	182,656 New	182,656 $403,000
Q3 2022 May 14, 2024	SELL	$1.18 - $2.19 $47,266 - $87,722	-40,056 Reduced 67.2%	19,553 $27,000
Q3 2022 Nov 10, 2022	SELL	$1.18 - $2.19 $47,266 - $87,722	-40,056 Reduced 67.2%	19,553 $0
Q2 2022 May 14, 2024	BUY	$1.28 - $2.23 $76,299 - $132,928	59,609 New	59,609 $104,000
Q2 2022 Aug 15, 2022	BUY	$1.28 - $2.23 $21,684 - $37,778	16,941 Added 39.7%	59,609 $104,000
Q1 2022 May 16, 2022	SELL	$1.85 - $4.59 $348,046 - $863,530	-188,133 Reduced 81.51%	42,668 $85,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.74 $507,578 - $1.25 Million	217,845 Added 1681.42%	230,801 $1.03 Million
Q3 2021 Nov 10, 2021	BUY	$6.01 - $11.26 $77,865 - $145,884	12,956 New	12,956 $78,000

15.9M

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.9M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.